



Geoffrey Levitt

Of Counsel

CO-CHAIR, FDA REGULATORY PRACTICE

geoffrey.levitt@dlapiper.com

Washington, DC

T: +1 202 799 4212

F: +1 202 799 5212

M: +1 267 455 7079

Geoff Levitt is co-chair of DLA Piper's FDA Regulatory Practice group. He advises clients on a wide range of regulatory, policy and legislative issues impacting the healthcare and life sciences sectors.

Geoff previously served as senior vice president and chief counsel for Pfizer Inc.'s Upjohn division in China, as chief regulatory counsel for Pfizer Inc. and Wyeth Pharmaceuticals, and as head of international affairs and policy for Viatrix Inc. At Pfizer, he was responsible for managing global legal support for regulatory, medical, safety, clinical research, manufacturing and environmental operations.

Geoff has published and lectured extensively on regulatory law. He is a past member of the editorial board of the Food and Drug Law Journal and past Chairman of the Board of the Food and Drug Law Institute. He has also served as Chair of the PhRMA Law Section Executive Committee.

Prior to joining Wyeth and Pfizer, Geoff headed the FDA regulatory practice at a major law firm in Washington, DC, where he represented a wide range of pharmaceutical and medical device clients on GxP compliance, exclusivity and approval issues.

- Litigation, Arbitration and Investigations

- Healthcare

Admisión

- District of Columbia

Formación

- J.D., Harvard Law School
- B.A., Political Science, Columbia University

Publicaciones

The moral imperative: Balancing innovation, regulation and prescription drug availability

21 March 2022

At the Intersection of Science and Law Podcast Series

Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky to discuss the importance of – and complications in - balancing biopharmaceutical innovation, industry regulations and prescription drug availability.

NOTICIAS

DLA Piper announces new practice leadership

18 February 2022

DLA Piper is pleased to announce several changes to sub-practice leadership in its Finance, Corporate, Private Equity, Regulatory and Government Affairs, and Litigation practices.

Geoffrey Levitt joins DLA Piper's Litigation and Regulatory practice as co-chair of Life Sciences Policy and Regulatory group

22 March 2021

DLA Piper announced today that Geoffrey Levitt has joined the firm's Litigation and Regulatory practice as co-chair of the Life Sciences Policy and Regulatory group.

MEDIA MENTIONS

- "Developing 'Antennae' for Drug Regulations and Policy: A Conversation with Geoffrey Levitt", *Biospace*, April 28, 2021
- "DLA Piper taps Morgan Lewis partner, Pfizer alum for practice leads," *Reuters*, March 24, 2021
- "Ex-Pfizer Atty Joins DLA Piper As It Bolsters Life Sciences," *Law360*, March 22, 2021
- "Pfizer's Ex-Chief Regulatory Counsel to Helm DLA Piper Practice", *Bloomberg Law*, March 22, 2021